Full Press Release Details
Prima BioMed Ltd Completion of Entitlement Offer
Prima BioMed Ltd ABN 90 009 237 889 (Company) is pleased to announce the successful completion of its 1 for 4 non-renounceable entitlement offer (Entitlement Offer) of options
(Options) to acquire fully paid ordinary shares in the Company.
The Entitlement Offer, raised a total of $1,547,574. As a consequence,
77,378,699 Options will be issued on Tuesday, 18 June 2013.
Gross proceeds from the Entitlement Offer, along with the funds raised from
the Company s recently completed share purchase plan (SPP) will be used to:
and to pay the costs of the Entitlement Offer and SPP.
It is expected that the Options will commence trading on ASX under the code PRRO on a normal (T+3) settlement basis on Wednesday, 19 June 2013.
further information regarding the Entitlement Offer, please see the prospectus lodged with the Australian Securities and Investments Commission and given to ASX in each case on 13 May 2013 or visit the Company s website
Prima BioMed is a globally active leader in the development of personalised bio-therapeutic products for cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximise value to shareholders. Prima BioMed s lead product is CVac , an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon
to be in trials for other cancer types.
The information contained in this announcement does not constitute an offer to sell securities or the solicitation of an offer to buy, or recommendation for investment in, any securities or financial
products within the United States or any other jurisdiction and does not and will not form any part of any contract for the acquisition of securities in the Company. In the United States, securities may not be sold absent registration or an
exemption from registration under the Securities Act. The information in this announcement is not intended as financial advice. Moreover, none of the information in this announcement is intended to constitute a prospectus within the meaning of the
applicable laws of any jurisdiction and this announcement is not directed to any person in any country in which the distribution of such information is unlawful. Moreover, you should be aware of the fact that investments in undertakings, securities
or other financial instruments involve risks. Past results do not guarantee future performance. This announcement contains certain forward-looking statements. The words intends , expected , proposed ,
forecast , target , and will and other similar expressions are intended to identify forward looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on
assumptions and contingencies which are subject to change without notice. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. There can be no assurance
that actual outcomes will not differ materially from these statements. This dates referred to in this announcement are indicative only and subject to change. The Company reserves the right, subject to the ASX Listing Rules and the Corporations Act
2001 (Cth), to alter the dates at its discretion, without prior notice.